CCA
IBB icon

Cravens & Co Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Cravens & Co Advisors’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,250
Closed -$214K – 67
2025
Q4 		$214K Buy
+1,250
New +$203K 0.14% 60

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Cravens & Co Advisors's IBB Position: Q1 2026 in Review

Cravens & Co Advisors sold out of iShares Biotechnology ETF (IBB) in Q1 2026, closing a stake of 1,250 shares — an estimated $214K sold.

Cravens & Co Advisors first reported a position in IBB in Q4 2025 and held it in 1 quarter. The position peaked at $214K in Q4 2025. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

  • Cravens & Co Advisors reported no remaining iShares Biotechnology ETF position as of Q1 2026 after selling out during the quarter.
  • Cravens & Co Advisors sold 1,250 iShares Biotechnology ETF shares in Q1 2026, an estimated $214K.
  • Cravens & Co Advisors first reported a position in iShares Biotechnology ETF in Q4 2025 and held it in 1 quarter.
  • Cravens & Co Advisors's iShares Biotechnology ETF position peaked at $214K in Q4 2025.
  • 917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Cravens & Co Advisors's 13F filing for Q1 2026, filed 14 May 2026.